Main Article Content
Selective laser trabeculoplasty (SLT) and micropulse laser trabeculoplasty (MLT) are well established, non-invasive laser procedures in glaucoma, but their place in the therapeutic algorithm still evolves. Lately published multicenter randomized clinical trials indicate the need to consider laser trabeculoplasty as the first-line treatment before medications in primary open-angle glaucoma an ocular hypertension due to its favorable safety profile, efficacy and cost-effectiveness. Subthreshold transscleral cyclophotocoagulation (present on the market under different brand names: SubCyclo® TS-CPC [Quantel, France] or Cyclo G6® mTS-CPC [Iridex, USA]) is an antiglaucomatous laser procedure, recently arousing more and more interest in ophthalmologists as a new non-invasive method in our therapeutic portfolio. This new device utilizes 810 nm diode laser beam, fractionated into ultra-short pulses, resulting in low energy spots without causing ciliary body coagulation. Subthreshold (or subliminal) energy delivered during the session spares the tissue due to very limited local heat accumulation zone and therefore this procedure may be repeated. Laser energy partially disables aqueous producing ciliary epithelium and opens supraciliary space thus activating the additional outflow facility. Subthreshold TS-CPC in several clinical trials proved to be effective in lowering the intraocular pressure and devoid of significant sight threatening side effects, comparing to the classical thermal diode cyclophotocoagulation method.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (email@example.com)
2. Garg A, Gazzard G. Selective laser trabeculoplasty: past, present, and future. Eye (Lond). 2018; 32: 863-76.
3. Leahy KE, White AJ. Selective laser trabeculoplasty: current perspectives. Clin Ophthalmol. 2015; 9: 833-41. http://doi.org/10.2147/OPTH.S53490.
4. Sanchez FG, Peirano-Bonomi JC, Grippo TM. Micropulse transscleral cyclophotocoagulation: a hypothesis for the ideal parameters. Med Hypothesis Discov Innov Ophthalmol. 2018; 7(3): 94-100.
5. Al Habash A, AlAhmadi AS. Outcome Of MicroPulse® Transscleral Photocoagulation In Different Types Of Glaucoma. Clin Ophthalmol. 2019; 13: 2353-60. http://doi.org/10.2147/OPTH.S226554.
6. Benhatchi N, Bensmail D, Lachkar Y. Benefits of SubCyclo Laser Therapy Guided by High-frequency Ultrasound Biomicroscopy in Patients With Refractory Glaucoma. J Glaucoma. 2019; 28(6): 535-9. http://doi.org/10.1097/IJG.0000000000001230.
7. Kuchar S, Moster M, Reamer CB et al. Treatment outcomes of micropulse transscleral cyclophotocoagulation in advanced glaucoma. Laser Med Sci. 2016; 31: 393-6. http://doi.org/10.1007/s10103-015-1856-9.
8. Gazzard G, Konstantakopoulou E, Garway-Heath D et al; LiGHT Trial Study Group. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet. 2019; 393(10180): 1505-16. http://doi.org/10.1016/S0140-6736(18)32213-X.
9. Garg A, Vickerstaff V, Nathwani N et al. Efficacy of repeat selective laser trabeculoplasty in medication-naive open-angle glaucoma and ocular hypertension during the LiGHT Trial. Ophthalmol. 2020; 127(4): 467-76. http://doi.org/10.1016/j.ophtha.2019.10.023.
10.Souissi S, Baudouin C, Labbé A et al. Micropulse transscleral cyclophotocoagulation using a standard protocol in patients with refractory glaucoma naive of cyclodestruction. Eur J Ophthalmol. 2019: 1120672119877586. http://doi.org/10.1177/1120672119877586.
11. Wright DM, Konstantakopoulou E, Montesano G et al; Laser in Glaucoma and Ocular Hypertension Trial (LiGHT) Study Group. Visual Field Outcomes from the Multicenter, Randomized Controlled Laser in Glaucoma and Ocular Hypertension Trial (LiGHT). Ophthalmology. 2020; 127(10): 1313-21. http://doi.org/10.1016/j.ophtha.2020.03.029.